{"title":"艾伯维将ii期抗体项目授权给嗜酸性食管炎受体","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I4.1914","DOIUrl":null,"url":null,"abstract":"Abbott spin-off AbbVie has licensed a deprioritised antibody programme to Receptos as part of a risk-sharing deal that allows the big pharma company to opt back into development and commercialisation of the drug candidate should it demonstrate proof-of-concept in the treatment of the orphan disease eosinophilic oesophagitis. ABT-308, a humanised anti-interleukin-13 (IL-13) monoclonal antibody that has been designated RPC4046 by Receptos, was well tolerated in a Phase I study in healthy volunteers and patients with mild-to-moderate persistent asthma.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"2013 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I4.1914\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abbott spin-off AbbVie has licensed a deprioritised antibody programme to Receptos as part of a risk-sharing deal that allows the big pharma company to opt back into development and commercialisation of the drug candidate should it demonstrate proof-of-concept in the treatment of the orphan disease eosinophilic oesophagitis. ABT-308, a humanised anti-interleukin-13 (IL-13) monoclonal antibody that has been designated RPC4046 by Receptos, was well tolerated in a Phase I study in healthy volunteers and patients with mild-to-moderate persistent asthma.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"2013 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-02-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I4.1914\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I4.1914","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis
Abbott spin-off AbbVie has licensed a deprioritised antibody programme to Receptos as part of a risk-sharing deal that allows the big pharma company to opt back into development and commercialisation of the drug candidate should it demonstrate proof-of-concept in the treatment of the orphan disease eosinophilic oesophagitis. ABT-308, a humanised anti-interleukin-13 (IL-13) monoclonal antibody that has been designated RPC4046 by Receptos, was well tolerated in a Phase I study in healthy volunteers and patients with mild-to-moderate persistent asthma.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
